ExSight Ventures

DTx Pharma develops technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across therapeutic areas. DTx Pharma believes its approach to delivering RNA medicines solves some of the issues that limited previous-generation platforms, including poor pharmacokinetics and insufficient cellular uptake.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections. Their delivery platforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers. Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more. The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.

DTx Pharma develops technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across therapeutic areas. DTx Pharma believes its approach to delivering RNA medicines solves some of the issues that limited previous-generation platforms, including poor pharmacokinetics and insufficient cellular uptake.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

LensGen is an ophthalmic medical device company that has developed a biomimetic, curvature changing fluid-optic intraocular lens designed for the treatment of cataracts and presbyopia. It offers Juvene™ which is designed to fit inside the same location as the natural human lens and adjusts dioptric power on demand through curvature change by using the same tiny muscle contractions that occur within the eye.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.